Changes in left ventricular structure and function in Type 2 diabetic patients, depending on the presence of cardiac autonomic neuropathy and metabolic syndrome components
Abstract
Aim. To assess the impact of cardiac autonomic neuropathy (CAP) on left ventricular (LV) structure and function in patients with Type 2 diabetes mellitus (DM-2), depending on the presence of metabolic syndrome (MS) components.
Material and methods. The study included 157 patients (128 women and 29 men) with DM-2. MS was diagnosed according to WHO criteria. CAN was detected based on the standard Ewing test (≥2 positive results). M-mode, B-mode, and Doppler echocardiography was performed in 4 clinical groups: Group I (n=14): CAN-negative, ≤1 MS component; Group II (n=16): CAN-negative, ≥2 MS components; Group III (n=19): CAN-positive, ≤1 MS component; and Group IV (n=108): CAN-positive, ≥2 MS components. LV geometry type, as well as LV systolic and diastolic function, was assessed according to the standard criteria.
Results. LV concentric hypertrophy (LVCH) was the most prevalent type of LV geometry in CAN-positive vs. CAN-negative patients (62,2% vs. 20,0%, respectively; p=0,02). The highest LVCH prevalence (63,9%) was registered in participants with CAN and ≥2 MS components. Over 50% of the patients with 0–1 MS component and two-thirds of the patients with ≥2 MS components had disturbed LV diastolic function. In the former, CAN presence did not affect the prevalence of diastolic dysfunction, while in the latter, diastolic dysfunction was significantly more prevalent among CAN-positive individuals (90,7%, compared to 56,2% in CAN-negative patients with ≥2 MS components; p=0,001).
Conclusion. In DM-2 patients, CAN was associated with LVCH andLV diastolic dysfunction. This association strengthened, as the number of MS components increased.
About the Authors
E. Yu. Lunina
Tver State Medical Academy
Russian Federation
Tver
Russian Federation
Tver
I. S. Petrukhin
Tver State Medical Academy
Russian Federation
Tver
Russian Federation
Tver
References
1. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005; 90: 5896–903.
2. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387–97.
3. Nishimura M, Hashimoto T, Kobayashi H, et al. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2532–8.
4. Mishra TK, Rath PK, Mohanty NK, Mishra SK. Left ventricular systolic and diastolic dysfunction and their relationship with microvascular complications in normotensive, asymptomatic patients with type 2 diabetes mellitus. Indian Heart J 2008; 60 (6): 548–53.
5. Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 2003; 29: 455–66.
6. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Geneva, World Health Org 1999.
7. Alberti KG, Zimmet PZ, Shaw J, the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059–62.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52.
9. Taslim S, Tai ES. The relevance of the metabolic syndrome. Ann Acad Med Singapore 2009; 38: 29–33.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–28.
11. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191–6.
12. Wong CY, O’Moore-Sullivan T, Leano R, et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110: 3081–7.
13. Iacobellis G, Ribaudo MC, Zappaterreno A, et al. Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res 2004; 12: 1616–21.
14. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334–41.
15. Kosmala W, O’Moore-Sullivan TM, Plaksej R, et al. Subclinical impairment of left ventricular function in young obese women: contributions of polycystic ovary disease and insulin resistance. J Clin Endocrinol Metab 2008, 93 (10): 3748–54.
16. Rutter M, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function. Sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448–54.
17. Aijaz B, Ammar KA, Lopez-Jimenez F, et al. Abnormal cardiac structure and function in the metabolic syndrome: A population-based study. Mayo Clin Proc 2008; 83 (12): 1350–7.
18. Azevedo A, Bettencourt P, Almeida PB, et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities – cross-sectional study of the general population. BMC Cardiovascular Disorders 2007; 7: 17–25.
19. Дедов И. И., Шестакова М. В., Максимова М. А. Федераль ная целевая программа «Сахарный диабет». Методические рекомен-дации. М 2002 – http://www.voed.ru/fcp_sd.htm
20. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies. A statement by the American Diabetes Association. Diabetes Care 2005; 28 (4): 956–62.
21. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491–8.
22. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387–97.
23. Рыбакова М. К., Алехин М. Н., Митьков В. В. Практическое руко-водство по ультразвуковой диагностике. Эхокардиография. М.: Издательский дом Видар. М 2008; 101–20.
24. European Study Group on Diastolic Heart Failure: How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990–1003.
25. Tsujino T, Kawasaki D, Masuyama T. Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications. Am J Cardiovasc Drugs 2006; 6 (4): 219–30.
26. Boyer JK, Thanigaraj S, Schechtman KB, Pörez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004; 93 (7): 870–5.
27. Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24: 5–10.
28. Chinali M, Devereux RB, Howard BV, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 93 (1): 40–4.
29. Grandi AM, Maresca AM, Giudici E, et al. Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens 2006; 19 (2): 199–205.
30. Burchfiel CM, Skelton TN, Andrew ME, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112 (6): 819–27.
31. Annonu AK, Fattah AA, Mokhtar MS, et al. Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus. J Am Soc Echocardiogr 2001; 14 (9): 885–91.
Review
For citations:
Lunina E.Yu., Petrukhin I.S. Changes in left ventricular structure and function in Type 2 diabetic patients, depending on the presence of cardiac autonomic neuropathy and metabolic syndrome components. Cardiovascular Therapy and Prevention. 2011;10(8):73-78. (In Russ.)
Views:
554
Email this article 
